PTD-DBM
Hair Growth / Wnt-Activating PeptideresearchAlso known as: Protein Transduction Domain-Dishevelled Binding Motif, PTD-DBM peptide
A cell-penetrating peptide that activates the Wnt/β-catenin signaling pathway to stimulate hair follicle neogenesis and promote hair growth, representing a novel approach to treating hair loss.
Overview
PTD-DBM is a synthetic peptide consisting of a protein transduction domain (PTD) fused to a Dishevelled-binding motif (DBM). It was developed by researchers at Yonsei University in South Korea as a topical treatment for hair loss. The peptide works by activating the Wnt/β-catenin signaling pathway, which is essential for hair follicle development, cycling, and regeneration. The Wnt pathway is suppressed in balding areas of the scalp, and its reactivation is considered a key target for hair restoration. The PTD component allows the peptide to penetrate cell membranes without requiring injection, enabling topical application. In preclinical studies, PTD-DBM promoted hair follicle neogenesis (formation of new follicles), accelerated hair growth, and increased hair density in mouse models. It represents a promising peptide-based alternative to finasteride and minoxidil, though human clinical data remains limited.
Mechanism of Action
PTD-DBM activates hair growth through Wnt signaling: (1) The PTD domain facilitates cellular uptake by crossing cell membranes; (2) The DBM portion binds to the CXXC domain of Dishevelled (Dvl) protein; (3) This interaction activates the canonical Wnt/β-catenin pathway; (4) β-catenin translocates to the nucleus and activates Wnt target genes (Axin2, LEF1, etc.); (5) Wnt activation promotes dermal papilla cell proliferation and hair follicle stem cell activation; (6) Induces anagen (growth phase) entry in resting hair follicles; (7) Promotes hair follicle neogenesis from stem cell populations; (8) Increases expression of hair growth factors including VEGF and IGF-1 in the dermal papilla.
Molecular Formula
Complex peptide — exact formula depends on specific construct
Molecular Weight
~3,000-4,000 Da (estimated)
Sequence
YARAAARQARA-SGSKSSESHSFR (PTD-DBM fusion)
Dosage Protocols
Dose Range
50mcg/ml – 500mcg/ml
Frequency
Once to twice daily
Route
topical (scalp application)
Cycle Length
12-24 weeks minimum
Dissolve in appropriate vehicle (water-based serum or liposomal carrier). Apply directly to thinning areas of scalp. Massage gently to enhance absorption. PTD domain enables cell penetration without injection. Experimental — no established human protocols.
Source: Preclinical research extrapolation and community protocols
Side Effects
| Effect | Severity |
|---|---|
| Scalp irritation | mild |
| Redness at application site | mild |
| Theoretical Wnt-related concerns | unknown |
Pros & Cons
Targets the Wnt/β-catenin pathway — a fundamental driver of hair follicle biology and neogenesis
Cell-penetrating PTD domain allows topical application without injection
Promotes actual hair follicle neogenesis, not just preservation of existing follicles
Novel mechanism distinct from finasteride (DHT blocker) and minoxidil (vasodilator)
Very early-stage research — only animal data, no human clinical trials
Wnt pathway activation raises theoretical oncological concerns, though topical delivery likely minimizes systemic risk
Limited commercial availability and quality control challenges
Optimal formulation and vehicle for topical delivery not yet established
Research Studies
Legal Status
Not FDA-approved. Preclinical/early research stage. Available from limited research peptide suppliers. No regulatory restrictions as a research compound.
Related Peptides
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Ipamorelin
A highly selective growth hormone-releasing peptide (GHRP) that stimulates GH release with minimal impact on cortisol, prolactin, or appetite, making it the cleanest GHRP available.
MK-677 (Ibutamoren)
An orally active, non-peptide growth hormone secretagogue that mimics ghrelin to raise GH and IGF-1 levels for up to 24 hours per dose, with notable effects on sleep, appetite, and body composition.
CJC-1295 (no DAC) / Mod GRF 1-29
A modified growth hormone-releasing hormone fragment with a short half-life (~30 minutes) that stimulates pulsatile growth hormone release, closely mimicking the body's natural GH secretion pattern.